Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30998824

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
JAMA Oncol
Publication date
2019 May 1
First author
Jackisch C

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Jackisch C
      type
      Author
    2. name
      Stroyakovskiy D
      type
      Author
    3. name
      Pivot X
      type
      Author
    4. name
      Ahn JS
      type
      Author
    5. name
      Melichar B
      type
      Author
    6. name
      Chen SC
      type
      Author
    7. name
      Meyenberg C
      type
      Author
    8. name
      Al-Sakaff N
      type
      Author
    9. name
      Heinzmann D
      type
      Author
    10. name
      Hegg R
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Jackisch C
      type
      Author
    2. name
      Stroyakovskiy D
      type
      Author
    3. name
      Pivot X
      type
      Author
    4. name
      Ahn JS
      type
      Author
    5. name
      Melichar B
      type
      Author
    6. name
      Chen SC
      type
      Author
    7. name
      Meyenberg C
      type
      Author
    8. name
      Al-Sakaff N
      type
      Author
    9. name
      Heinzmann D
      type
      Author
    10. name
      Hegg R
      type
      Author
    bibliography ids
    1. nci-bib-262f237d1a98f55b9c8ebec8
    book metadata
    content sha256
    eb1b4cff544f43623ab887ee7d509564cfd60b5645ee9751d2ca322d9e6837db
    document type
    citation
    dois
    1. 10.1001/jamaoncol.2019.0339
    electronic publication date
    display
    2019 May 9
    precision
    day
    year
    2019
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:30998824
    immutable id
    pubmed:30998824@eb1b4cff544f43623ab887ee7d509564cfd60b5645ee9751d2ca322d9e6837db
    journal
    abbreviation
    JAMA Oncol
    issn electronic
    2374-2445
    issn print
    2374-2437
    issue
    5
    name
    JAMA oncology
    nlm unique id
    101652861
    pages
    e190339
    volume
    5
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      30998824
      provenance
      batch id
      e808962322f3afebc564
      provider
      NCBI PubMed ESummary
      record sha256
      161f01ab72911e9feee4066a67c1a24889e5d351894cc7aaf41d99f9e4e3808a
      response sha256
      3d610336ca8dae92b82cdb6b3ee6cab382eb509e0349b0c68c261b042b036561
      retrieved at
      2026-09-09T23:47:41.002093+00:00
      publication date
      display
      2019 May 1
      precision
      day
      year
      2019
      publication types
      1. Clinical Trial, Phase III
      2. Journal Article
      3. Multicenter Study
      4. Randomized Controlled Trial
      5. Equivalence Trial
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/30998824/
      title
      Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial.

      Preserved source evidence · Not medical advice